TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02608905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
Study: NCT00328640
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00888901
Drug: corticosteroids (Aprednislon)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: corticosteroids in decreasing dosage
Study: NCT02100150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry flavored solution 0.5% v/v in Water for Injection
Study: NCT00928512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
Study: NCT00086294
Drug: Intravenous Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00086294
Drug: ACP-103
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02585596
Drug: YH23537 1000mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH23537 500mg 2 tab
Study: NCT02585596
Drug: YH23537 2000mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH23537 500mg 4 tab
Study: NCT02585596
Drug: YH23537 3000mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH23537 500mg 6 tab
Study: NCT02585596
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH23537 500mg tab placebo
Study: NCT02661503
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02661503
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00084643
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT03202095
Drug: Creatine Monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 grams daily of oral creatine monohydrate powder.
Study: NCT03126214
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
Study: NCT03170193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of matching placebo by SC or IV injection
Study: NCT02901483
Drug: PEP503
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP503 will be administered by intratumoral route as slow injection
Study: NCT03539367
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT00296023
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02359513
Drug: Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: bulimic patients are treated during 3 months
Study: NCT03335280
Drug: 68Ga-citrate PET/MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
Study: NCT02544828
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (normal saline) is administered after anesthesia induction
Study: NCT02446795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
Study: NCT02720822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo is given as one double-blind capsule in the morning.
Study: NCT02720822
Drug: Plus laxative (Docusate with senna)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If patients are taking morphine, a laxative will be offered. This applies whatever the dose of morphine being taken (8mg, 16mg, 24mg or 32 mg).
Study: NCT02720822
Drug: Plus placebo laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the patients are taking placebo, a placebo laxative will be offered.
Study: NCT01818063
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01818063
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02774564
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebicapone tablets 50 mg, oral administration
Study: NCT02774564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebicapone matching placebo tablets
Study: NCT02774564
Drug: Sinemet®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
Study: NCT01919398
Drug: LY2940680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01766414
Drug: Endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously
Study: NCT04885426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03796598
Drug: Fecal Microbial transplant Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules of FMT
Study: NCT03002922
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen formula Y65-158
Study: NCT01837797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, tablets, orally
Study: NCT00004758
Drug: pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04381936
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
Study: NCT04381936
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
Study: NCT00567957
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
Study: NCT04399356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The collection of oropharyngeal samples will be observed by a Study Team member via the telehealth platform.
Study: NCT03254160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01543412
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
Study: NCT04107428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
Study: NCT03052816
Drug: Motrin/Percocet/Dilaudid for breakthrough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen
Study: NCT01000025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 45 mg PO, daily
Study: NCT01361373
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 2 weeks
Study: NCT00612157
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03918447
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing an inert placebo
Study: NCT00975988
Drug: TYKERB® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients administrated TYKERB® tablets according to the prescribing information
Study: NCT00885989
Drug: SLV338
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 - 1000 mg IV
Study: NCT00885989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00669903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00408434
Drug: CS-7017
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-7017 0.05mg and 1.0mg tablets
Study: NCT02259894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02110264
Drug: XR-NTX
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
Study: NCT00128115
Drug: MK0677
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00975052
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo only on Days 1 and 2 in one of four treatment periods.
Study: NCT01083420
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 0.2% mouthwash
Study: NCT01601717
Drug: RTI-336
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
Study: NCT01601717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo pill administered once per day for 10 days.
Study: NCT00387036
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
Study: NCT00767767
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Saline infusion for 2 hours.
Study: NCT01678820
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg tablet
Study: NCT01678820
Drug: Placebo to simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to simvastatin 40 mg tablet
Study: NCT02059161
Drug: MK-1293
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Study: NCT02059161
Drug: Lantus™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Study: NCT01629680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: coated tablets identical in number and appearance as the study drug
Study: NCT02991144
Drug: Reactive Corticosteroid Taper Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301.
Study: NCT02991144
Drug: Prophylactic Corticosteroid Taper Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisone \[or oral prednisolone\] 60 mg/day at least 5 days prior to DTX301 administration, tapered over 9 weeks.~A prophylactic corticosteroid taper regimen will be administered to prevent or minimize transient vector-induced hepatic effects.
Study: NCT00007475
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For GFR \> 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR \< 50 ml/min/1.73 m2 but \> 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
Study: NCT03311022
Drug: Acupan® 30mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00642135
Drug: Mydriasert®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
Study: NCT00258180
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV over 1 hour on days 1-4
Study: NCT02912468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study: NCT00125593
Drug: Simvastatin 20 mg
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily
Study: NCT00125593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT01953770
Drug: Low-dose Methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
Study: NCT01953770
Drug: Triple intrathecal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
Study: NCT01916941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00432510
Drug: C1 esterase inhibitor [human] (C1INH-nf)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02724527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo capsule
Study: NCT02168543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01805557
Drug: R-DHAP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy
Study: NCT00930943
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg qd twice
Study: NCT00003471
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with a recurrent/progressive low grade astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01031472
Drug: GSK2248761 formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
Study: NCT01031472
Drug: GSK2248761 reference formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 100mg Gelucire reference capsule with food
Study: NCT01031472
Drug: GSK2248761 formulation 3
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
Study: NCT01031472
Drug: GSK2248761 formulation 2 or 4
Normalized name: Inova 8-2 Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
Study: NCT00960752
Drug: R848 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
Study: NCT01719601
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
Study: NCT00061113
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg, QD x 16 weeks
Study: NCT01351025
Drug: placebo for atorvastin
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
Study: NCT00615134
Drug: Optimized background ARV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00525603
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2/day 3-5 IV 5-30 minutes
Study: NCT03513601
Drug: (R)-CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: (rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
Study: NCT00280657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
Study: NCT00097708
Drug: experimental anti-anxiety drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03510624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty capsules
Study: NCT01861522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Placebo tablets will be taken orally twice a day
Study: NCT01789047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT01357330
Drug: SAR245408 (XL147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule and tablet Route of administration: oral
Study: NCT01357330
Drug: MSC1936369B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT02390739
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
Study: NCT04755023
Drug: Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
Normalized name: bis(β-chloroethyl)methylamine
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
Study: NCT01805557
Drug: BR-DHAP
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Bortezomib SC 1.5 mg/sqm day 1, day 4~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days.
Study: NCT04307173
Drug: KBL693
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral
Study: NCT04307173
Drug: KBL693
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral
Study: NCT00810589
Drug: Humalog NPL Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,4 IE per kg bodyweight
Study: NCT03886922
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
Study: NCT00078286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage ranging from 50 mg to 200 mg once a day
Study: NCT00832364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules